

Jonathan A Coleman

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/5472360/jonathan-a-coleman-publications-by-year.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

214
papers

9,546
citations

43
h-index

93
g-index

235
ext. papers

12,192
ext. citations

5.6
avg, IF

5.72
L-index

#	Paper	IF	Citations
214	Reply by Authors.. <i>Journal of Urology</i> , 2022 , 101097JU0000000000000235002	2.5	1
213	Vascular-Targeted Photodynamic Therapy for Prostate Cancer 2021 , 249-255		
212	Predictors of long-term renal function after kidney surgery for patients with preoperative chronic kidney disease. <i>Canadian Urological Association Journal</i> , 2021 , 15, E103-E109	1.2	
211	Neoadjuvant vascular-targeted photodynamic therapy improves survival and reduces recurrence and progression in a mouse model of urothelial cancer. <i>Scientific Reports</i> , 2021 , 11, 4842	4.9	0
210	Inguinal hernia of the distal ureter causing hydronephrosis: A rare case. <i>Urology Case Reports</i> , 2021 , 35, 101549	0.5	1
209	A qualitative framework of non-selection factors for cytoreductive nephrectomy. <i>World Journal of Urology</i> , 2021 , 39, 3359-3365	4	2
208	Comprehensive Molecular Characterization and Response to Therapy in Fumarate Hydratase-Deficient Renal Cell Carcinoma. <i>Clinical Cancer Research</i> , 2021 , 27, 2910-2919	12.9	8
207	A systematic review of outcomes after thermal and nonthermal partial prostate ablation.. <i>Prostate International</i> , 2021 , 9, 169-175	3.4	3
206	Single-cell sequencing links multiregional immune landscapes and tissue-resident T cells in ccRCC to tumor topology and therapy efficacy. <i>Cancer Cell</i> , 2021 , 39, 662-677.e6	24.3	28
205	Molecular classification and diagnostics of upper urinary tract urothelial carcinoma. <i>Cancer Cell</i> , 2021 , 39, 793-809.e8	24.3	13
204	Resource-efficient pooled sequencing expands translational impact in solid tumors. <i>Kidney Cancer Journal: Official Journal of the Kidney Cancer Association</i> , 2021 , 19, 18-23	0.1	0
203	Combined OX40 Agonist and PD-1 Inhibitor Immunotherapy Improves the Efficacy of Vascular Targeted Photodynamic Therapy in a Urothelial Tumor Model. <i>Molecules</i> , 2021 , 26,	4.8	2
202	Prevalence and Landscape of Actionable Genomic Alterations in Renal Cell Carcinoma. <i>Clinical Cancer Research</i> , 2021 , 27, 5595-5606	12.9	3
201	Can kidney parenchyma metabolites serve as prognostic biomarkers for long-term kidney function after nephrectomy for renal cell carcinoma? A preliminary study.. <i>CKJ: Clinical Kidney Journal</i> , 2021 , 14, 656-664	4.5	
200	The Clinicopathologic and Molecular Landscape of Clear Cell Papillary Renal Cell Carcinoma: Implications in Diagnosis and Management. <i>European Urology</i> , 2021 , 79, 468-477	10.2	9
199	Summary from the Kidney Cancer Association's Inaugural Think Thank: Coalition for a Cure. <i>Clinical Genitourinary Cancer</i> , 2021 , 19, 167-175	3.3	1
198	Positron Emission Tomography/Computed Tomography with Gallium-68-labeled Prostate-specific Membrane Antigen Detects Relapse After Vascular-targeted Photodynamic Therapy in a Prostate Cancer Model. <i>European Urology Focus</i> , 2021 , 7, 472-478	5.1	1

197	Putative Drivers of Aggressiveness in TCEB1-mutant Renal Cell Carcinoma: An Emerging Entity with Variable Clinical Course. <i>European Urology Focus</i> , 2021 , 7, 381-389	5.1	7
196	Focal therapy for primary and salvage prostate cancer treatment: a narrative review. <i>Translational Andrology and Urology</i> , 2021 , 10, 3144-3154	2.3	
195	Therapy-relevant gene signatures in the high risk localized renal cell carcinoma setting: Transcriptomic data from patients receiving placebo on a randomized phase III trial (PROTECT).. <i>Journal of Clinical Oncology</i> , 2021 , 39, 353-353	2.2	
194	Photoselective Vaporization of the Prostate in the Management of Lower Urinary Tract Symptoms in Prostate Cancer Patients on Active Surveillance. <i>Urology</i> , 2021 , 156, 225-230	1.6	0
193	Evolving biological associations of upfront cytoreductive nephrectomy in metastatic renal cell carcinoma. <i>Cancer</i> , 2021 , 127, 3946-3956	6.4	2
192	Defining the index lesion for potential salvage partial or hemi-gland ablation after radiation therapy for localized prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021 , 39, 495.e17-495.e24	2.8	
191	A comparison of oncologic and functional outcomes in patients with pt3a renal cell carcinoma treated with partial and radical nephrectomy. <i>International Braz J Urol: Official Journal of the Brazilian Society of Urology</i> , 2021 , 47, 777-783	2	3
190	Robotic colectomy and repair of colovesical fistula due to diverticulitis - a video vignette. <i>Colorectal Disease</i> , 2021 , 23, 3045-3046	2.1	
189	Somatic mutations as preoperative predictors of metastases in patients with localized clear cell renal cell carcinoma - An exploratory analysis. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021 , 39, 791.e17-791.e24	2.8	0
188	Durability of Response to Primary Chemoablation of Low-Grade Upper Tract Urothelial Carcinoma Using UGN-101, a Mitomycin-Containing Reverse Thermal Gel: OLYMPUS Trial Final Report.. <i>Journal of Urology</i> , 2021 , 101097JU00000000000002350	2.5	3
187	Standardized Nomenclature and Surveillance Methodologies After Focal Therapy and Partial Gland Ablation for Localized Prostate Cancer: An International Multidisciplinary Consensus. <i>European Urology</i> , 2020 , 78, 371-378	10.2	28
186	Importance of long-term follow-up after endoscopic management for upper tract urothelial carcinoma and factors leading to surgical management. <i>International Urology and Nephrology</i> , 2020 , 52, 1465-1469	2.3	1
185	High-resolution optoacoustic imaging of tissue responses to vascular-targeted therapies. <i>Nature Biomedical Engineering</i> , 2020 , 4, 286-297	19	46
184	Patient-Derived Xenograft Models in Urological Malignancies: Urothelial Cell Carcinoma and Renal Cell Carcinoma. <i>Cancers</i> , 2020 , 12,	6.6	4
183	An evaluation of the role of tumor load in cytoreductive nephrectomy. <i>Canadian Urological Association Journal</i> , 2020 , 14, E625-E630	1.2	0
182	Routine Postoperative Hemoglobin Assessment Poorly Predicts Transfusion Requirement among Patients Undergoing Minimally Invasive Radical Prostatectomy. <i>Urology Practice</i> , 2020 , 7, 299-304	0.8	0
181	Primary chemoablation of low-grade upper tract urothelial carcinoma using UGN-101, a mitomycin-containing reverse thermal gel (OLYMPUS): an open-label, single-arm, phase 3 trial. <i>Lancet Oncology, The</i> , 2020 , 21, 776-785	21.7	38
180	Modeling biological and genetic diversity in upper tract urothelial carcinoma with patient derived xenografts. <i>Nature Communications</i> , 2020 , 11, 1975	17.4	17

179	The Role of Cytoreductive Nephrectomy for Sarcomatoid Renal Cell Carcinoma: A 29-Year Institutional Experience. <i>Urology</i> , 2020 , 136, 169-175	1.6	6
178	Transcriptomic signatures related to the obesity paradox in patients with clear cell renal cell carcinoma: a cohort study. <i>Lancet Oncology</i> , 2020 , 21, 283-293	21.7	55
177	The Association Between Small Primary Tumor Size and Prognosis in Metastatic Renal Cell Carcinoma: Insights from Two Independent Cohorts of Patients Who Underwent Cytoreductive Nephrectomy. <i>European Urology Oncology</i> , 2020 , 3, 47-56	6.7	12
176	Cancer Susceptibility Mutations in Patients With Urothelial Malignancies. <i>Journal of Clinical Oncology</i> , 2020 , 38, 406-414	2.2	31
175	Preoperative nomogram predicting 12-year probability of metastatic renal cancer - evaluation in a contemporary cohort. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020 , 38, 853.e1-853.e7	2.8	0
174	Developments in Vascular-Targeted Photodynamic Therapy for Urologic Malignancies. <i>Molecules</i> , 2020 , 25,	4.8	6
173	Impact of intraoperative opioid and adjunct analgesic use on renal cell carcinoma recurrence: role for onco-anaesthesia. <i>British Journal of Anaesthesia</i> , 2020 , 125, e402-e404	5.4	6
172	Value of Partial Nephrectomy for Renal Cortical Tumors of cT2 or Greater Stage: A Risk-benefit Analysis of Renal Function Preservation Versus Increased Postoperative Morbidity. <i>European Urology Oncology</i> , 2020 , 3, 365-371	6.7	7
171	Comprehensive Genomic Analysis of Translocation Renal Cell Carcinoma Reveals Copy-Number Variations as Drivers of Disease Progression. <i>Clinical Cancer Research</i> , 2020 , 26, 3629-3640	12.9	16
170	Phase III Trial of Intravenous Mannitol Versus Placebo During Nephron-sparing Surgery: Post Hoc Analysis of 3-yr Outcomes. <i>European Urology Focus</i> , 2019 , 5, 977-979	5.1	3
169	Clinicopathologic features associated with survival after cytoreductive nephrectomy for nonclear cell renal cell carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019 , 37, 811.e9-811.e16 ⁸	4	4
168	Effectiveness of the combination of vascular targeted photodynamic therapy and anti-cytotoxic T-lymphocyte-associated antigen4 in a preclinical mouse model of urothelial carcinoma. <i>International Journal of Urology</i> , 2019 , 26, 414-422	2.3	5
167	Contemporary Management of Hemorrhage After Minimally Invasive Radical Prostatectomy. <i>Urology</i> , 2019 , 130, 120-125	1.6	3
166	Macrophage-secreted TGF- β contributes to fibroblast activation and ureteral stricture after ablation injury. <i>American Journal of Physiology - Renal Physiology</i> , 2019 , 317, F52-F64	4.3	26
165	Potentiating vascular-targeted photodynamic therapy through CSF-1R modulation of myeloid cells in a preclinical model of prostate cancer. <i>Oncotarget</i> , 2019 , 8, e1581528	7.2	11
164	Temporal changes in MRI appearance of the prostate after focal ablation. <i>Abdominal Radiology</i> , 2019 , 44, 272-278	3	7
163	Familial Kidney Cancer: Implications of New Syndromes and Molecular Insights. <i>European Urology</i> , 2019 , 76, 754-764	10.2	42
162	Chromophobe Renal Cell Carcinoma: Results From a Large Single-Institution Series. <i>Clinical Genitourinary Cancer</i> , 2019 , 17, 373-379.e4	3.3	20

161	The predictive role of preoperative and postoperative neutrophil-lymphocyte ratio in sarcomatoid renal cell carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019 , 37, 916-923	2.8	3
160	Abnormal oxidative metabolism in a quiet genomic background underlies clear cell papillary renal cell carcinoma. <i>ELife</i> , 2019 , 8,	8.9	17
159	Examining Mannitol Use in Kidney Cancer Surgery: A Cautionary Tale of Extrapolated Surgical Data. <i>European Urology Focus</i> , 2019 , 5, 930-934	5.1	1
158	Clonal Relatedness and Mutational Differences between Upper Tract and Bladder Urothelial Carcinoma. <i>Clinical Cancer Research</i> , 2019 , 25, 967-976	12.9	94
157	Epidemiology of Renal Cell Carcinoma. <i>European Urology</i> , 2019 , 75, 74-84	10.2	446
156	Prognostic Value of TERT Alterations, Mutational and Copy Number Alterations Burden in Urothelial Carcinoma. <i>European Urology Focus</i> , 2019 , 5, 201-204	5.1	18
155	Characterization and Impact of TERT Promoter Region Mutations on Clinical Outcome in Renal Cell Carcinoma. <i>European Urology Focus</i> , 2019 , 5, 642-649	5.1	27
154	Characterizing recurrent and lethal small renal masses in clear cell renal cell carcinoma using recurrent somatic mutations. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019 , 37, 12-17	2.8	17
153	Genomic Profile of Urothelial Carcinoma of the Upper Tract from Ureteroscopic Biopsy: Feasibility and Validation Using Matched Radical Nephroureterectomy Specimens. <i>European Urology Focus</i> , 2019 , 5, 365-368	5.1	9
152	Androgen Deprivation Therapy Potentiates the Efficacy of Vascular Targeted Photodynamic Therapy of Prostate Cancer Xenografts. <i>Clinical Cancer Research</i> , 2018 , 24, 2408-2416	12.9	15
151	Cystic Renal Cell Carcinoma: A Report on Outcomes of Surgery and Active Surveillance in Patients Retrospectively Identified on Pretreatment Imaging. <i>Journal of Urology</i> , 2018 , 200, 275-282	2.5	15
150	Misclassification of Upper Tract Urothelial Carcinoma in Patients With Lynch Syndrome. <i>JAMA Oncology</i> , 2018 , 4, 1010	13.4	3
149	Tumor Evolution and Drug Response in Patient-Derived Organoid Models of Bladder Cancer. <i>Cell</i> , 2018 , 173, 515-528.e17	56.2	310
148	Pirfenidone inhibits cryoablation induced local macrophage infiltration along with its associated TGFb1 expression and serum cytokine level in a mouse model. <i>Cryobiology</i> , 2018 , 82, 106-111	2.7	6
147	Timing of blood transfusion and oncologic outcomes in patients treated with radical nephroureterectomy for upper tract urothelial carcinoma. <i>World Journal of Urology</i> , 2018 , 36, 645-653	4	2
146	The Effect of Patient and Surgical Characteristics on Renal Function After Partial Nephrectomy. <i>Clinical Genitourinary Cancer</i> , 2018 , 16, 191-196	3.3	5
145	Importance of wide re-resection in adult spermatic cord sarcomas: Report on oncologic outcomes at a single institution. <i>Journal of Surgical Oncology</i> , 2018 , 117, 1464-1468	2.8	4
144	Comparative Genomic Profiling of Matched Primary and Metastatic Tumors in Renal Cell Carcinoma. <i>European Urology Focus</i> , 2018 , 4, 986-994	5.1	20

143	Systemic Antitumor Immunity by PD-1/PD-L1 Inhibition Is Potentiated by Vascular-Targeted Photodynamic Therapy of Primary Tumors. <i>Clinical Cancer Research</i> , 2018 , 24, 592-599	12.9	47
142	Intravenous Mannitol Versus Placebo During Partial Nephrectomy in Patients with Normal Kidney Function: A Double-blind, Clinically-integrated, Randomized Trial. <i>European Urology</i> , 2018 , 73, 53-59	10.2	32
141	WST11 Vascular Targeted Photodynamic Therapy Effect Monitoring by Multispectral Optoacoustic Tomography (MSOT) in Mice. <i>Theranostics</i> , 2018 , 8, 723-734	12.1	33
140	Randomized Trial of Partial Gland Ablation with Vascular Targeted Phototherapy versus Active Surveillance for Low Risk Prostate Cancer: Extended Followup and Analyses of Effectiveness. <i>Journal of Urology</i> , 2018 , 200, 786-793	2.5	41
139	Can pelvic node dissection at radical prostatectomy influence the nodal recurrence at salvage lymphadenectomy for prostate cancer?. <i>Investigative and Clinical Urology</i> , 2018 , 59, 83-90	1.9	7
138	The natural history of large renal masses followed on observation. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018 , 36, 362.e17-362.e21	2.8	6
137	The association of renal cell carcinoma with gastrointestinal stromal tumors. <i>Journal of Surgical Oncology</i> , 2018 , 117, 1716-1720	2.8	3
136	Renal function recovery after radical nephroureterectomy for upper tract urothelial carcinoma. <i>World Journal of Urology</i> , 2018 , 36, 257-263	4	7
135	Genomic Characterization of Upper-Tract Urothelial Carcinoma in Patients With Lynch Syndrome. <i>JCO Precision Oncology</i> , 2018 , 2018,	3.6	15
134	Randomized Trial Comparing Open Radical Cystectomy and Robot-assisted Laparoscopic Radical Cystectomy: Oncologic Outcomes. <i>European Urology</i> , 2018 , 74, 465-471	10.2	114
133	Prevalence of Germline Mutations in Cancer Susceptibility Genes in Patients With Advanced Renal Cell Carcinoma. <i>JAMA Oncology</i> , 2018 , 4, 1228-1235	13.4	66
132	Update of the ICUD-SIU consultation on upper tract urothelial carcinoma 2016: treatment of low-risk upper tract urothelial carcinoma. <i>World Journal of Urology</i> , 2017 , 35, 355-365	4	27
131	Association between lymph node yield and survival among patients undergoing radical nephroureterectomy for urothelial carcinoma of the upper tract. <i>Cancer</i> , 2017 , 123, 1741-1750	6.4	18
130	Validation of 3D volumetric-based renal function prediction calculator for nephron sparing surgery. <i>International Urology and Nephrology</i> , 2017 , 49, 615-621	2.3	1
129	Utility of prospective pathologic evaluation to inform clinical genetic testing for hereditary leiomyomatosis and renal cell carcinoma. <i>Cancer</i> , 2017 , 123, 2452-2458	6.4	9
128	Bombesin Antagonist-Based Radiotherapy of Prostate Cancer Combined with WST-11 Vascular Targeted Photodynamic Therapy. <i>Clinical Cancer Research</i> , 2017 , 23, 3343-3351	12.9	14
127	Alkaline phosphatase velocity predicts overall survival and bone metastasis in patients with castration-resistant prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2017 , 35, 460.e21-460.e28	2.8	18
126	Genomic alterations as predictors of survival among patients within a combined cohort with clear cell renal cell carcinoma undergoing cytoreductive nephrectomy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2017 , 35, 532.e7-532.e13	2.8	17

125	Analysis of renal cancer cell lines from two major resources enables genomics-guided cell line selection. <i>Nature Communications</i> , 2017 , 8, 15165	17.4	40
124	Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients. <i>Nature Medicine</i> , 2017 , 23, 703-713	50.5	1638
123	A Comparative Study of Ablation Boundary Sharpness After Percutaneous Radiofrequency, Cryo-, Microwave, and Irreversible Electroporation Ablation in Normal Swine Liver and Kidneys. <i>CardioVascular and Interventional Radiology</i> , 2017 , 40, 1600-1608	2.7	19
122	Normal Porcine Ureter Retains Lumen Wall Integrity but Not Patency Following Catheter-Directed Irreversible Electroporation: Imaging and Histologic Assessment over 28 Days. <i>Journal of Vascular and Interventional Radiology</i> , 2017 , 28, 913-919.e1	2.4	16
121	Clinical Outcomes in Patients with Panurothelial Carcinoma Treated with Radical Nephroureterectomy Following Cystectomy for Metachronous Recurrence. <i>Journal of Urology</i> , 2017 , 198, 546-551	2.5	3
120	Prognostic value of lymph node yield during nephroureterectomy for upper tract urothelial carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2017 , 35, 151.e9-151.e15	2.8	8
119	Benign and tumor parenchyma metabolomic profiles affect compensatory renal growth in renal cell carcinoma surgical patients. <i>PLoS ONE</i> , 2017 , 12, e0180350	3.7	1
118	Biopsy of Small Renal Masses Should be Routinely Performed before Deciding Treatment: Con. <i>Journal of Urology</i> , 2017 , 198, 757-759	2.5	
117	Mutation Detection in Patients With Advanced Cancer by Universal Sequencing of Cancer-Related Genes in Tumor and Normal DNA vs Guideline-Based Germline Testing. <i>JAMA - Journal of the American Medical Association</i> , 2017 , 318, 825-835	27.4	235
116	The difficulty in selecting patients for cytoreductive nephrectomy: An evaluation of previously described predictive models. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2017 , 35, 35.e1-35.e5	2.8	18
115	Upper Urinary Tract Carcinoma In Situ: Current Knowledge, Future Direction. <i>Journal of Urology</i> , 2017 , 197, 287-295	2.5	25
114	Tumor Xenografts of Human Clear Cell Renal Cell Carcinoma But Not Corresponding Cell Lines Recapitulate Clinical Response to Sunitinib: Feasibility of Using Biopsy Samples. <i>European Urology Focus</i> , 2017 , 3, 590-598	5.1	21
113	Integration of Recurrent Somatic Mutations with Clinical Outcomes: A Pooled Analysis of 1049 Patients with Clear Cell Renal Cell Carcinoma. <i>European Urology Focus</i> , 2017 , 3, 421-427	5.1	29
112	Nephrometry scores and perioperative outcomes following robotic partial nephrectomy. <i>International Braz J Urol: Official Journal of the Brazilian Society of Urology</i> , 2017 , 43, 1075-1083	2	6
111	Irreversible Electroporation for Prostate Cancer as Salvage Treatment Following Prior Radiation and Cryotherapy. <i>Reviews in Urology</i> , 2017 , 19, 268-272	1	3
110	An Arterial Based Complexity (ABC) Scoring System to Assess the Morbidity Profile of Partial Nephrectomy. <i>European Urology</i> , 2016 , 69, 72-9	10.2	47
109	The Prognostic Impact of a Positive Vascular Margin on pT3 Clear Cell Renal Cell Carcinoma. <i>Journal of Urology</i> , 2016 , 195, 264-9	2.5	11
108	Tumor immune microenvironment characterization in clear cell renal cell carcinoma identifies prognostic and immunotherapeutically relevant messenger RNA signatures. <i>Genome Biology</i> , 2016 , 17, 231	18.3	391

107	Final Results of a Phase I/II Multicenter Trial of WST11 Vascular Targeted Photodynamic Therapy for Hemi-Ablation of the Prostate in Men with Unilateral Low Risk Prostate Cancer Performed in the United States. <i>Journal of Urology</i> , 2016 , 196, 1096-104	2.5	41
106	Impact of Uteroscopy Before Nephroureterectomy for Upper Tract Urothelial Carcinoma on Oncologic Outcomes. <i>Urology</i> , 2016 , 94, 148-53	1.6	22
105	Treatment Effects of WST11 Vascular Targeted Photodynamic Therapy for Urothelial Cell Carcinoma in Swine. <i>Journal of Urology</i> , 2016 , 196, 236-43	2.5	13
104	Comparison of ablation defect on MR imaging with computer simulation estimated treatment zone following irreversible electroporation of patient prostate. <i>SpringerPlus</i> , 2016 , 5, 219		9
103	Low yield of surveillance imaging after surgery for T1 kidney cancer. <i>World Journal of Urology</i> , 2016 , 34, 949-53	4	2
102	Prognostic Genetic Signatures in Upper Tract Urothelial Carcinoma. <i>Current Urology Reports</i> , 2016 , 17, 12	2.9	23
101	Nonthermal Ablation by Using Intravascular Oxygen Radical Generation with WST11: Dynamic Tissue Effects and Implications for Focal Therapy. <i>Radiology</i> , 2016 , 281, 109-18	20.5	18
100	The effect of delaying nephrectomy on oncologic outcomes in patients with renal tumors greater than 4cm. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2016 , 34, 239.e1-8	2.8	14
99	Genomic Biomarkers for the Prediction of Stage and Prognosis of Upper Tract Urothelial Carcinoma. <i>Journal of Urology</i> , 2016 , 195, 1684-1689	2.5	27
98	Erectile Function Recovery after Radical Prostatectomy in Men with High Risk Features. <i>Journal of Urology</i> , 2016 , 196, 507-13	2.5	11
97	The Efficacy of Multiparametric Magnetic Resonance Imaging and Magnetic Resonance Imaging Targeted Biopsy in Risk Classification for Patients with Prostate Cancer on Active Surveillance. <i>Journal of Urology</i> , 2016 , 196, 374-81	2.5	51
96	Outcome of genetic evaluation of patients with kidney cancer referred for suspected hereditary cancer syndromes. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2016 , 34, 238.e1-7	2.8	11
95	Feasibility of a Modified Biopsy Needle for Irreversible Electroporation Ablation and Periprocedural Tissue Sampling. <i>Technology in Cancer Research and Treatment</i> , 2016 , 15, 749-758	2.7	3
94	Validation and genomic interrogation of the MET variant rs11762213 as a predictor of adverse outcomes in clear cell renal cell carcinoma. <i>Cancer</i> , 2016 , 122, 402-10	6.4	13
93	Comparative Effectiveness of Targeted Prostate Biopsy Using Magnetic Resonance Imaging Ultrasound Fusion Software and Visual Targeting: a Prospective Study. <i>Journal of Urology</i> , 2016 , 196, 697-702	2.5	33
92	Second primary malignancies in renal cortical neoplasms: an updated evaluation from a single institution. <i>World Journal of Urology</i> , 2016 , 34, 1667-1672	4	5
91	Pilot Study to Assess Safety and Clinical Outcomes of Irreversible Electroporation for Partial Gland Ablation in Men with Prostate Cancer. <i>Journal of Urology</i> , 2016 , 196, 883-90	2.5	39
90	Predicting length of stay after robotic partial nephrectomy. <i>International Urology and Nephrology</i> , 2015 , 47, 1321-5	2.3	10

89	Feasibility of catheter-directed intraluminal irreversible electroporation of porcine ureter and acute outcomes in response to increasing energy delivery. <i>Journal of Vascular and Interventional Radiology</i> , 2015 , 26, 1059-66	2.4	23
88	Ambulatory Extended Recovery: Safely Transitioning to Overnight Observation for Minimally Invasive Prostatectomy. <i>Urology Practice</i> , 2015 , 2, 121-125	0.8	4
87	Cost comparison of open and robotic partial nephrectomy using a short postoperative pathway. <i>Urology</i> , 2015 , 85, 596-603	1.6	22
86	Salvage ablative therapy in prostate cancer: international multidisciplinary consensus on trial design. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015 , 33, 495.e1-7	2.8	11
85	Patterns of Lymphatic Metastases in Upper Tract Urothelial Carcinoma and Proposed Dissection Templates. <i>Journal of Urology</i> , 2015 , 194, 1567-74	2.5	51
84	Genomic Characterization of Upper Tract Urothelial Carcinoma. <i>European Urology</i> , 2015 , 68, 970-7	10.2	147
83	Interobserver variability of R.E.N.A.L., PADUA, and centrality index nephrometry score systems. <i>World Journal of Urology</i> , 2015 , 33, 853-8	4	34
82	Planning irreversible electroporation in the porcine kidney: are numerical simulations reliable for predicting empiric ablation outcomes?. <i>CardioVascular and Interventional Radiology</i> , 2015 , 38, 182-90	2.7	19
81	Preoperative predictive model of recovery of urinary continence after radical prostatectomy. <i>BJU International</i> , 2015 , 116, 577-83	5.6	54
80	Functional outcomes of partial prostate ablation and focal therapy: are we managing expectations of a bar set too high?. <i>Current Opinion in Urology</i> , 2015 , 25, 220-4	2.8	4
79	Comparing Open Radical Cystectomy and Robot-assisted Laparoscopic Radical Cystectomy: A Randomized Clinical Trial. <i>European Urology</i> , 2015 , 67, 1042-1050	10.2	337
78	TCEB1-mutated renal cell carcinoma: a distinct genomic and morphological subtype. <i>Modern Pathology</i> , 2015 , 28, 845-853	9.8	76
77	Focal Therapy: Current Status and Future Directions 2015 , 235-246		
76	Impact of a common clinical pathway on length of hospital stay in patients undergoing open and minimally invasive kidney surgery. <i>Journal of Urology</i> , 2014 , 191, 1225-30	2.5	27
75	MP77-14 CAN PRE-OPERATIVE CT IDENTIFY POSITIVE LYMPH NODES IN PATIENTS WITH UPPER TRACT UROTHELIAL CARCINOMA?. <i>Journal of Urology</i> , 2014 , 191,	2.5	6
74	The impact of genetic heterogeneity on biomarker development in kidney cancer assessed by multiregional sampling. <i>Cancer Medicine</i> , 2014 , 3, 1485-92	4.8	95
73	Preliminary evaluation of urinary soluble Met as a biomarker for urothelial carcinoma of the bladder. <i>Journal of Translational Medicine</i> , 2014 , 12, 199	8.5	12
72	MRI-safe robot for targeted transrectal prostate biopsy: animal experiments. <i>BJU International</i> , 2014 , 113, 977-85	5.6	17

71	Comparison of perioperative outcomes of retroperitoneal and transperitoneal minimally invasive partial nephrectomy after adjusting for tumor complexity. <i>Urology</i> , 2014 , 84, 1355-60	1.6	28
70	Establishing a neoadjuvant platform for developing targeted agents: Degarelix prior to prostatectomy for patients with intermediate- and high-risk prostate cancer.. <i>Journal of Clinical Oncology</i> , 2014 , 32, TPS5105-TPS5105	2.2	2
69	Targeted sequencing of upper tract urothelial carcinoma.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 309-309	2.2	2
68	Validation and genomic interrogation of the MET variant rs11762213 as a predictor of adverse outcomes in clear cell renal cell carcinoma.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 395-395	2.2	1
67	Association of baseline health and gender with small renal mass pathology.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 515-515	2.2	
66	Postoperative nomogram for disease recurrence and cancer-specific death for upper tract urothelial carcinoma: comparison to American Joint Committee on Cancer staging classification. <i>Urology Journal</i> , 2014 , 11, 1435-41	0.9	19
65	MRI-Safe Robot for Endorectal Prostate Biopsy. <i>IEEE/ASME Transactions on Mechatronics</i> , 2013 , 19, 1289-1299	5.1	85
64	Impact of smoking status at diagnosis on disease recurrence and death in upper tract urothelial carcinoma. <i>BJU International</i> , 2013 , 111, 589-95	5.6	20
63	Accuracy analysis in MRI-guided robotic prostate biopsy. <i>International Journal of Computer Assisted Radiology and Surgery</i> , 2013 , 8, 937-44	3.9	17
62	Clinical and pathologic impact of select chromatin-modulating tumor suppressors in clear cell renal cell carcinoma. <i>European Urology</i> , 2013 , 63, 848-54	10.2	168
61	Contemporary role of systematic prostate biopsies: indications, techniques, and implications for patient care. <i>European Urology</i> , 2013 , 63, 214-30	10.2	163
60	846 OPTIMAL PARAMETERS FOR THE DELIVERY OF VASCULAR TARGETED PHOTODYNAMIC THERAPY IN THE BLADDER, RENAL PELVIS, AND URETER. <i>Journal of Urology</i> , 2013 , 189,	2.5	1
59	Follow-up for Clinically Localized Renal Neoplasms: AUA Guideline. <i>Journal of Urology</i> , 2013 , 190, 407-16	2.5	226
58	A case-mix-adjusted comparison of early oncological outcomes of open and robotic prostatectomy performed by experienced high volume surgeons. <i>BJU International</i> , 2013 , 111, 206-12	5.6	32
57	Endoscopic spray cryotherapy for genitourinary malignancies: safety and efficacy in a porcine model. <i>Therapeutic Advances in Urology</i> , 2013 , 5, 135-41	3.2	5
56	Targeted prostate cancer ablation: energy options. <i>Current Opinion in Urology</i> , 2013 , 23, 123-8	2.8	14
55	Factors that affect proportional glomerular filtration rate after minimally invasive partial nephrectomy. <i>Journal of Endourology</i> , 2013 , 27, 1371-5	2.7	9
54	Transperineal Mapping Biopsy of the Prostate for Assessment of the Minimal Risk Patient 2013 , 277-284		

53 Surgical Approaches to Treatment of Renal Cell Carcinoma **2013**, 699-711

52	Comparison of open and minimally invasive partial nephrectomy for renal tumors 4-7 centimeters. <i>European Urology</i> , 2012 , 61, 593-9	10.2	61
51	Transatlantic Consensus Group on active surveillance and focal therapy for prostate cancer. <i>BJU International</i> , 2012 , 109, 1636-47	5.6	88
50	Feasibility study of a clinically-integrated randomized trial of modifications to radical prostatectomy. <i>Trials</i> , 2012 , 13, 23	2.8	4
49	Improved clinical outcomes with high-dose image guided radiotherapy compared with non-IGRT for the treatment of clinically localized prostate cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012 , 84, 125-9	4	347
48	Pelvic lymph node dissection for patients with elevated risk of lymph node invasion during radical prostatectomy: comparison of open, laparoscopic and robot-assisted procedures. <i>Journal of Endourology</i> , 2012 , 26, 748-53	2.7	40
47	Intraoperative mannitol use does not improve long-term renal function outcomes after minimally invasive partial nephrectomy. <i>Urology</i> , 2012 , 79, 821-5	1.6	40
46	Assessing renal function after partial nephrectomy using renal nuclear scintigraphy and estimated glomerular filtration rate. <i>Urology</i> , 2012 , 80, 343-6	1.6	27
45	Combining imaging and ureteroscopy variables in a preoperative multivariable model for prediction of muscle-invasive and non-organ confined disease in patients with upper tract urothelial carcinoma. <i>BJU International</i> , 2012 , 109, 77-82	5.6	136
44	Renal oncocytosis: management and clinical outcomes. <i>Journal of Urology</i> , 2011 , 185, 795-801	2.5	21
43	Renal tissue ablation with irreversible electroporation: preliminary results in a porcine model. <i>Urology</i> , 2011 , 77, 754-60	1.6	88
42	Extent of pelvic lymph node dissection and the impact of standard template dissection on nomogram prediction of lymph node involvement. <i>European Urology</i> , 2011 , 60, 195-201	10.2	73
41	Reply from Authors re: R. Jeffrey Karnes. To What Extent Can We Predict Prostate Cancer Lymph Node Involvement? <i>Eur Urol</i> 2011;60:202B. <i>European Urology</i> , 2011 , 60, 204	10.2	
40	Temporal trends and predictors of pelvic lymph node dissection in open or minimally invasive radical prostatectomy. <i>Cancer</i> , 2011 , 117, 3933-42	6.4	68
39	Lymph node dissection during robotic-assisted laparoscopic prostatectomy: comparison of lymph node yield and clinical outcomes when including common iliac nodes with standard template dissection. <i>BJU International</i> , 2010 , 106, 391-6	5.6	21
38	140 ROLE OF 3D TRANSPERINEAL MAPPING BIOPSY IN CANDIDATES FOR ACTIVE SURVEILLANCE. <i>Journal of Urology</i> , 2010 , 183,	2.5	1
37	Focal treatment or observation of prostate cancer: pretreatment accuracy of transrectal ultrasound biopsy and T2-weighted MRI. <i>Urology</i> , 2010 , 75, 472-7	1.6	37
36	Extended pelvic lymph node dissection in robotic-assisted radical prostatectomy: surgical technique and initial experience. <i>Urology</i> , 2010 , 75, 1199-204	1.6	43

35	Critical evaluation of perioperative complications in laparoscopic partial nephrectomy. <i>Urology</i> , 2010 , 75, 288-94	1.6	21
34	Genitourinary cancer predisposition syndromes. <i>Hematology/Oncology Clinics of North America</i> , 2010 , 24, 861-83	3.1	3
33	128 TEMPORAL TRENDS IN THE OPERATIVE MANAGEMENT OF PELVIC LYMPH NODES IN PATIENTS RECEIVING OPEN OR MINIMALLY INVASIVE RADICAL PROSTATECTOMY. <i>Journal of Urology</i> , 2010 , 183,	2.5	2
32	Analysis of secreted proteins for the study of bladder cancer cell aggressiveness. <i>Journal of Proteome Research</i> , 2010 , 9, 3243-59	5.6	42
31	Recovery of renal function after open and laparoscopic partial nephrectomy. <i>European Urology</i> , 2010 , 58, 596-601	10.2	27
30	The effect of tumor location on prognosis in patients treated with radical nephroureterectomy at Memorial Sloan-Kettering Cancer Center. <i>European Urology</i> , 2010 , 58, 574-80	10.2	129
29	Comparison between laparoscopic and open radical nephroureterectomy in a contemporary group of patients: are recurrence and disease-specific survival associated with surgical technique?. <i>European Urology</i> , 2010 , 58, 645-51	10.2	81
28	Chromosomal and proteome analysis of a new T24-based cell line model for aggressive bladder cancer. <i>Proteomics</i> , 2009 , 9, 287-98	4.8	25
27	Metastatic renal cell carcinoma risk according to tumor size. <i>Journal of Urology</i> , 2009 , 182, 41-5	2.5	137
26	Hereditary and familial kidney cancer. <i>Current Opinion in Urology</i> , 2009 , 19, 478-85	2.8	33
25	Comparison of gelatine matrix-thrombin sealants used during laparoscopic partial nephrectomy. <i>BJU International</i> , 2008 , 102, 1670-4	5.6	20
24	Editorial comment on: MR-guided biopsy of the prostate: an overview of techniques and a systematic review. <i>European Urology</i> , 2008 , 54, 525-6	10.2	1
23	Prognostic indicators of malignancy in adrenal pheochromocytomas: clinical, histopathologic, and cell cycle/apoptosis gene expression analysis. <i>Surgery</i> , 2008 , 143, 759-68	3.6	132
22	New treatments for localized prostate cancer. <i>Urology</i> , 2008 , 72, S36-43	1.6	45
21	Evaluating localized prostate cancer and identifying candidates for focal therapy. <i>Urology</i> , 2008 , 72, S12-24		101
20	Familial and hereditary renal cancer syndromes. <i>Urologic Clinics of North America</i> , 2008 , 35, 563-72; v	2.9	39
19	Current and future imaging for urologic interventions. <i>Current Opinion in Urology</i> , 2008 , 18, 116-21	2.8	10
18	Focal treatment of prostate cancer with vascular-targeted photodynamic therapy. <i>Scientific World Journal, The</i> , 2008 , 8, 963-73	2.2	20

17	Patient selection determines the prostate cancer yield of dynamic contrast-enhanced magnetic resonance imaging-guided transrectal biopsies in a closed 3-Tesla scanner. <i>BJU International</i> , 2008 , 101, 181-5	5.6	27
16	Familial renal carcinoma: clinical evaluation, clinical subtypes and risk of renal carcinoma development. <i>Journal of Urology</i> , 2007 , 177, 461-5; discussion 465	2.5	23
15	Hereditary leiomyomatosis and renal cell cancer: a syndrome associated with an aggressive form of inherited renal cancer. <i>Journal of Urology</i> , 2007 , 177, 2074-9; discussion 2079-80	2.5	191
14	Magnetic resonance imaging-directed transrectal ultrasonography-guided biopsies in patients at risk of prostate cancer. <i>BJU International</i> , 2007 , 99, 1041-6	5.6	46
13	Radiofrequency-assisted laparoscopic partial nephrectomy: clinical and histologic results. <i>Journal of Endourology</i> , 2007 , 21, 600-5	2.7	19
12	Identification of the genes for kidney cancer: opportunity for disease-specific targeted therapeutics. <i>Clinical Cancer Research</i> , 2007 , 13, 671s-679s	12.9	113
11	Advances in imaging for urologic procedures. <i>Nature Reviews Urology</i> , 2007 , 4, 498-504		4
10	c-Met ectodomain shedding rate correlates with malignant potential. <i>Clinical Cancer Research</i> , 2006 , 12, 4154-62	12.9	64
9	Transrectal prostate biopsy and fiducial marker placement in a standard 1.5T magnetic resonance imaging scanner. <i>Journal of Urology</i> , 2006 , 175, 113-20	2.5	86
8	Intrarectal amifostine suspension may protect against acute proctitis during radiation therapy for prostate cancer: a pilot study. <i>International Journal of Radiation Oncology Biology Physics</i> , 2006 , 65, 1008-13	4.13	26
7	Radiofrequency ablation for tumor-related massive hematuria. <i>Journal of Vascular and Interventional Radiology</i> , 2005 , 16, 417-21	2.4	24
6	Design of a novel MRI compatible manipulator for image guided prostate interventions. <i>IEEE Transactions on Biomedical Engineering</i> , 2005 , 52, 306-13	5	228
5	An Interventional Magnetic Resonance Imaging Technique for the Molecular Characterization of Intraprostatic Dynamic Contrast Enhancement. <i>Molecular Imaging</i> , 2005 , 4, 153535002005041	3.7	14
4	An interventional magnetic resonance imaging technique for the molecular characterization of intraprostatic dynamic contrast enhancement. <i>Molecular Imaging</i> , 2005 , 4, 63-6	3.7	7
3	Adult spermatic cord sarcomas: management and results. <i>Annals of Surgical Oncology</i> , 2003 , 10, 669-75	3.1	108
2	Ultrasound characterization of the infertile male testis with rf power spectrum analysis 2002 , 4687, 147		
1	Prostate ablations 265-282		